Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Completed · Phase 1

Conditions studied: Giant Cell Arteritis, Polymyalgia Rheumatica

In brief

This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics \[PK\]) and whether it will be safe and tolerable after multiple doses of i.v. Secukinumab infusion in adult patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR).

Key facts

Study ID
NCT06130540
Run by
Novartis Pharmaceuticals
People needed
65
Starts
2024-03-27
Expected to finish
2025-04-02
Last updated by the study team
2026-04-01

Who can join

Age: 50 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.